COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip; Global COVID-19 Thrombosis Collaborative Group

doi:10.1016/j.jacc.2020.04.031

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Behnood Bikdeli, Mahesh V Madhavan, David Jimenez, Taylor Chuich, Isaac Dreyfus, Elissa Driggin, Caroline Der Nigoghossian, Walter Ageno, Mohammad Madjid, Yutao Guo, Liang V Tang, Yu Hu, Jay Giri, Mary Cushman, Isabelle Quéré, Evangelos P Dimakakos, C Michael Gibson, Giuseppe Lippi, Emmanuel J Favaloro, Jawed FareedJoseph A Caprini, Alfonso J Tafur, John R Burton, Dominic P Francese, Elizabeth Y Wang, Anna Falanga, Claire McLintock, Beverley J Hunt, Alex C Spyropoulos, Geoffrey D Barnes, John W Eikelboom, Ido Weinberg, Sam Schulman, Marc Carrier, Gregory Piazza, Joshua A Beckman, P Gabriel Steg, Gregg W Stone, Stephan Rosenkranz, Samuel Z Goldhaber, Sahil A Parikh, Manuel Monreal, Harlan M Krumholz, Stavros V Konstantinides, Jeffrey I Weitz, Gregory Y H Lip, Global COVID-19 Thrombosis Collaborative Group

Research output: Contribution to journal › Review article › peer-review

2353 Citations (Scopus)

Abstract

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

Original language	English
Journal	Journal of the American College of Cardiology
Volume	75
Issue number	23
Pages (from-to)	2950-2973
Number of pages	24
ISSN	0735-1097
DOIs	https://doi.org/10.1016/j.jacc.2020.04.031
Publication status	Published - 16 Jun 2020

Bibliographical note

Keywords

COVID-19
SARS-CoV-2
anticoagulant
antiplatelet
antithrombotic therapy
thrombosis

Access to Document

10.1016/j.jacc.2020.04.031

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164881/pdf/main.pdf

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., Nigoghossian, C. D., Ageno, W., Madjid, M., Guo, Y., Tang, L. V., Hu, Y., Giri, J., Cushman, M., Quéré, I., Dimakakos, E. P., Gibson, C. M., Lippi, G., Favaloro, E. J., ... Global COVID-19 Thrombosis Collaborative Group (2020). COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 75(23), 2950-2973. https://doi.org/10.1016/j.jacc.2020.04.031

@article{8ce0008346d142f596229f77a5d259de,

title = "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review",

abstract = "Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.",

keywords = "COVID-19, SARS-CoV-2, anticoagulant, antiplatelet, antithrombotic therapy, thrombosis",

author = "Behnood Bikdeli and Madhavan, {Mahesh V} and David Jimenez and Taylor Chuich and Isaac Dreyfus and Elissa Driggin and Nigoghossian, {Caroline Der} and Walter Ageno and Mohammad Madjid and Yutao Guo and Tang, {Liang V} and Yu Hu and Jay Giri and Mary Cushman and Isabelle Qu{\'e}r{\'e} and Dimakakos, {Evangelos P} and Gibson, {C Michael} and Giuseppe Lippi and Favaloro, {Emmanuel J} and Jawed Fareed and Caprini, {Joseph A} and Tafur, {Alfonso J} and Burton, {John R} and Francese, {Dominic P} and Wang, {Elizabeth Y} and Anna Falanga and Claire McLintock and Hunt, {Beverley J} and Spyropoulos, {Alex C} and Barnes, {Geoffrey D} and Eikelboom, {John W} and Ido Weinberg and Sam Schulman and Marc Carrier and Gregory Piazza and Beckman, {Joshua A} and Steg, {P Gabriel} and Stone, {Gregg W} and Stephan Rosenkranz and Goldhaber, {Samuel Z} and Parikh, {Sahil A} and Manuel Monreal and Krumholz, {Harlan M} and Konstantinides, {Stavros V} and Weitz, {Jeffrey I} and Lip, {Gregory Y H} and {Global COVID-19 Thrombosis Collaborative Group}",

year = "2020",

month = jun,

day = "16",

doi = "10.1016/j.jacc.2020.04.031",

language = "English",

volume = "75",

pages = "2950--2973",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier",

number = "23",

}

Bikdeli, B, Madhavan, MV, Jimenez, D, Chuich, T, Dreyfus, I, Driggin, E, Nigoghossian, CD, Ageno, W, Madjid, M, Guo, Y, Tang, LV, Hu, Y, Giri, J, Cushman, M, Quéré, I, Dimakakos, EP, Gibson, CM, Lippi, G, Favaloro, EJ, Fareed, J, Caprini, JA, Tafur, AJ, Burton, JR, Francese, DP, Wang, EY, Falanga, A, McLintock, C, Hunt, BJ, Spyropoulos, AC, Barnes, GD, Eikelboom, JW, Weinberg, I, Schulman, S, Carrier, M, Piazza, G, Beckman, JA, Steg, PG, Stone, GW, Rosenkranz, S, Goldhaber, SZ, Parikh, SA, Monreal, M, Krumholz, HM, Konstantinides, SV, Weitz, JI, Lip, GYH & Global COVID-19 Thrombosis Collaborative Group 2020, 'COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review', Journal of the American College of Cardiology, vol. 75, no. 23, pp. 2950-2973. https://doi.org/10.1016/j.jacc.2020.04.031

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. / Bikdeli, Behnood; Madhavan, Mahesh V; Jimenez, David et al.
In: Journal of the American College of Cardiology, Vol. 75, No. 23, 16.06.2020, p. 2950-2973.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - COVID-19 and Thrombotic or Thromboembolic Disease

T2 - Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

AU - Bikdeli, Behnood

AU - Madhavan, Mahesh V

AU - Jimenez, David

AU - Chuich, Taylor

AU - Dreyfus, Isaac

AU - Driggin, Elissa

AU - Nigoghossian, Caroline Der

AU - Ageno, Walter

AU - Madjid, Mohammad

AU - Guo, Yutao

AU - Tang, Liang V

AU - Hu, Yu

AU - Giri, Jay

AU - Cushman, Mary

AU - Quéré, Isabelle

AU - Dimakakos, Evangelos P

AU - Gibson, C Michael

AU - Lippi, Giuseppe

AU - Favaloro, Emmanuel J

AU - Fareed, Jawed

AU - Caprini, Joseph A

AU - Tafur, Alfonso J

AU - Burton, John R

AU - Francese, Dominic P

AU - Wang, Elizabeth Y

AU - Falanga, Anna

AU - McLintock, Claire

AU - Hunt, Beverley J

AU - Spyropoulos, Alex C

AU - Barnes, Geoffrey D

AU - Eikelboom, John W

AU - Weinberg, Ido

AU - Schulman, Sam

AU - Carrier, Marc

AU - Piazza, Gregory

AU - Beckman, Joshua A

AU - Steg, P Gabriel

AU - Stone, Gregg W

AU - Rosenkranz, Stephan

AU - Goldhaber, Samuel Z

AU - Parikh, Sahil A

AU - Monreal, Manuel

AU - Krumholz, Harlan M

AU - Konstantinides, Stavros V

AU - Weitz, Jeffrey I

AU - Lip, Gregory Y H

AU - Global COVID-19 Thrombosis Collaborative Group

PY - 2020/6/16

Y1 - 2020/6/16

N2 - Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

AB - Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.

KW - COVID-19

KW - SARS-CoV-2

KW - anticoagulant

KW - antiplatelet

KW - antithrombotic therapy

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85084432174&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2020.04.031

DO - 10.1016/j.jacc.2020.04.031

M3 - Review article

C2 - 32311448

SN - 0735-1097

VL - 75

SP - 2950

EP - 2973

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 23

ER -

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Abstract

Bibliographical note

Keywords

Access to Document

AUB Link

Other files and links

Fingerprint

Cite this